10.88

0.27% -0.03

After Hours: 10.88

Oric Pharmaceuticals Inc (ORIC)

Overview News Price History Option Chain Financials Discussions Forecast

Oric Pharmaceuticals Inc stock is traded at $10.88, with a volume of 2.45M. It is down -0.27% in the last 24 hours and up +45.07% over the past month. ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Previous Close:

$10.91

Open:

$10.95

24h Volume:

2.45M

Relative Volume:

1.25

Market Cap:

$1.13B

Revenue:

Net Income/Loss:

$-135.21M

P/E Ratio:

-7.6025

EPS:

-1.4311

Net Cash Flow:

$-114.35M

1W Performance:

+0.46%

1M Performance:

+45.07%

6M Performance:

+25.35%

1Y Performance:

+2.16%

1-Day Range:

$10.29

$11.05

1-Week Range:

$10.29

$12.06

52-Week Range:

$7.23

$14.93

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name

Oric Pharmaceuticals Inc

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

(650) 388-5600

Address

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Employee

104

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

ORIC's Discussions on Twitter

Compare ORIC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORIC Oric Pharmaceuticals Inc	10.88	1.13B	0	-135.21M	-114.35M	-1.4311
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Initiated	Piper Sandler	Overweight
Nov-20-25	Initiated	Evercore ISI	Outperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-04-25	Resumed	Guggenheim	Buy
Jul-08-25	Initiated	Ladenburg Thalmann	Buy
Oct-31-24	Initiated	Wells Fargo	Overweight
Sep-06-24	Initiated	Stifel	Buy
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-21	Upgrade	Citigroup	Neutral → Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Aug-13-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Upgrade	Citigroup	Neutral → Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Citigroup	Neutral
May-19-20	Initiated	Guggenheim	Buy
May-19-20	Initiated	JP Morgan	Overweight
May-19-20	Initiated	Jefferies	Buy

View All

Oric Pharmaceuticals Inc Stock (ORIC) Latest News

11:57 AM

ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth - AD HOC NEWS

11:57 AM

06:22 AM

Price to sales forward of Oric Pharmaceuticals, Inc. – DUS:4TZ - TradingView

06:22 AM

Jul 06, 2026

ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan - Stock Titan

Jul 06, 2026

[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan

Jul 06, 2026

ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits

Jul 06, 2026

Jul 03, 2026

Oric Pharmaceuticals stock extends rally with bullish signals after 22 percent weekly surge - Traders Union

Jul 03, 2026

Jul 02, 2026

ORIC awards new hires 44,400 stock options and 7,200 RSUs - Stock Titan

Jul 02, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 02, 2026

Jun 29, 2026

Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation - MSN

Jun 29, 2026

Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView

Jun 29, 2026

Jun 28, 2026

Price to earnings forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView

Jun 28, 2026

Price to book forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView

Jun 28, 2026

Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView

Jun 28, 2026

Behavioral Patterns of ORIC and Institutional Flows - Stock Traders Daily

Jun 28, 2026

Jun 26, 2026

ORIC gains as Stifel resumes at buy on upcoming Pfizer readout - MSN

Jun 26, 2026

Oric Pharmaceuticals stock trades up as price holds above key supports despite mixed momentum - Traders Union

Jun 26, 2026

Oric Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ORIC) - TradingView

Jun 26, 2026

Jun 25, 2026

ORIC Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Jun 24, 2026

Jun 22, 2026

Oric Shareholders Approve Equity Plan, Governance Measures - TipRanks

Jun 22, 2026

ORIC Pharmaceuticals (ORIC) shareholders back updated equity plan and annual say-on-pay - Stock Titan

Jun 22, 2026